MX341976B - Formulaciones de darunavir. - Google Patents

Formulaciones de darunavir.

Info

Publication number
MX341976B
MX341976B MX2013015196A MX2013015196A MX341976B MX 341976 B MX341976 B MX 341976B MX 2013015196 A MX2013015196 A MX 2013015196A MX 2013015196 A MX2013015196 A MX 2013015196A MX 341976 B MX341976 B MX 341976B
Authority
MX
Mexico
Prior art keywords
darunavir
formulations
darunavir formulations
solvate
pharmaceutically acceptable
Prior art date
Application number
MX2013015196A
Other languages
English (en)
Other versions
MX2013015196A (es
Inventor
Eugeen Maria Jozef Jans
Philip Erna H Heyns
Urbain Alfons C Delaet
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of MX2013015196A publication Critical patent/MX2013015196A/es
Publication of MX341976B publication Critical patent/MX341976B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a formas farmacéuticas orales sólidas del inhibidor de VIH darunavir y/o uno de sus solvatos o sales farmacéuticamente aceptable, y formulaciones combinadas este.
MX2013015196A 2011-07-07 2012-07-06 Formulaciones de darunavir. MX341976B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11173066 2011-07-07
PCT/EP2012/063242 WO2013004816A1 (en) 2011-07-07 2012-07-06 Darunavir formulations

Publications (2)

Publication Number Publication Date
MX2013015196A MX2013015196A (es) 2014-08-18
MX341976B true MX341976B (es) 2016-09-07

Family

ID=46458539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015196A MX341976B (es) 2011-07-07 2012-07-06 Formulaciones de darunavir.

Country Status (23)

Country Link
US (3) US20140142174A1 (es)
EP (1) EP2729128B1 (es)
JP (1) JP6101260B2 (es)
KR (1) KR101817991B1 (es)
CN (1) CN103841962B (es)
AU (1) AU2012280277B2 (es)
BR (1) BR112014000195A2 (es)
CA (1) CA2837539C (es)
CY (1) CY1119446T1 (es)
DK (1) DK2729128T3 (es)
EA (1) EA026588B1 (es)
ES (1) ES2598823T3 (es)
HR (1) HRP20161340T1 (es)
HU (1) HUE030341T2 (es)
IL (1) IL229700B (es)
LT (1) LT2729128T (es)
MX (1) MX341976B (es)
PL (1) PL2729128T3 (es)
PT (1) PT2729128T (es)
RS (1) RS55236B1 (es)
SI (1) SI2729128T1 (es)
SM (1) SMT201600380B (es)
WO (1) WO2013004816A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651212T3 (es) 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2016067090A1 (en) 2014-10-26 2016-05-06 King Abdullah University Of Science And Technology Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (hiv)
BR112020000842A2 (pt) 2017-07-20 2020-07-21 Janssen Sciences Ireland Unlimited Company composições e métodos para tratamento do hiv
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
MX2022013090A (es) * 2020-04-20 2022-11-14 Poviva Corp Composiciones y metodos para el suministro mejorado de agentes antivirales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
RU2010102067A (ru) * 2007-06-25 2011-07-27 Тиботек Фармасьютикалз (Ie) Комбинированные композиции, включающие дарунавир и этравирин
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
PT2477992T (pt) * 2009-09-17 2017-03-20 Mylan Laboratories Ltd Processos para a preparação de darunavir e a forma amorfa do mesmo

Also Published As

Publication number Publication date
JP2014520786A (ja) 2014-08-25
PL2729128T3 (pl) 2017-05-31
KR101817991B1 (ko) 2018-01-12
SI2729128T1 (sl) 2016-11-30
ES2598823T3 (es) 2017-01-30
US20160113949A1 (en) 2016-04-28
DK2729128T3 (en) 2016-11-21
IL229700B (en) 2018-04-30
EP2729128A1 (en) 2014-05-14
EA201490223A1 (ru) 2014-06-30
KR20140068844A (ko) 2014-06-09
HUE030341T2 (en) 2017-05-29
US20210244749A1 (en) 2021-08-12
EP2729128B1 (en) 2016-07-27
US20140142174A1 (en) 2014-05-22
SMT201600380B (it) 2017-01-10
MX2013015196A (es) 2014-08-18
PT2729128T (pt) 2016-09-21
CY1119446T1 (el) 2018-04-04
LT2729128T (lt) 2016-11-10
CN103841962A (zh) 2014-06-04
CA2837539C (en) 2021-08-10
RS55236B1 (sr) 2017-02-28
AU2012280277A1 (en) 2013-12-19
CN103841962B (zh) 2016-08-17
CA2837539A1 (en) 2013-01-10
IL229700A0 (en) 2014-01-30
WO2013004816A1 (en) 2013-01-10
BR112014000195A2 (pt) 2017-02-21
EA026588B1 (ru) 2017-04-28
JP6101260B2 (ja) 2017-03-22
HRP20161340T1 (hr) 2016-12-02
AU2012280277B2 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
MX343689B (es) Formulaciones combinadas de darunavir.
MX341976B (es) Formulaciones de darunavir.
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP3256149A4 (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
MY163083A (en) Solid forms of a pharmaceutically active substance
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
MX348823B (es) Formulaciones estables de linaclotida.
MY187718A (en) Pharmaceutical formulations
MX2013004190A (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
IN2014DN10670A (es)
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
TN2015000135A1 (en) Modified release formulations for oprozomib
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EP3402488A4 (en) SOLID ORAL PHARMACEUTICAL FORMS OF ESLICARBAZEPINE
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
WO2014122671A3 (en) Solid oral compositions of saxagliptin
MX2013008559A (es) Derivados de leptina.
MX2011009844A (es) Composicion farmaceutica que comprende alisquireno.
GB2569616B (en) Sustained release oral pharmaceutical compositions of dicycloverine

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: JANSSEN SCIENCES IRELAND UC

FG Grant or registration